Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179


HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G, Budman DR, Henderson IC, Barcos M, Hayes D, Norton L.

J Clin Oncol. 2000 Oct 15;18(20):3471-9.


Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.

Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC.

J Clin Oncol. 2003 Feb 1;21(3):453-7.


erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET.

J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60.


Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.

J Clin Oncol. 2005 Jul 1;23(19):4287-97.


p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L.

Clin Cancer Res. 2000 Jul;6(7):2751-8.


Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG)..

J Natl Cancer Inst. 2002 Jul 17;94(14):1054-65. Erratum in: J Natl Cancer Inst 2002 Sep 4;94(17):1339.


Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America..

Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6.


Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.

Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, et al.

Clin Cancer Res. 1995 Feb;1(2):189-98.


Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

International Breast Cancer Study Group., Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.

J Clin Oncol. 2006 Mar 20;24(9):1332-41.


Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients.

Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K; Takeda Adjuvant Breast Cancer Study with Leuprorelin Study Group..

Breast Cancer Res Treat. 2003 Aug;80(3):245-55.


Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.

Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG.

J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82.


Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.

Martin M, Brase JC, Calvo L, Krappmann K, Ruiz-Borrego M, Fisch K, Ruiz A, Weber KE, Munarriz B, Petry C, Rodriguez CA, Kronenwett R, Crespo C, Alba E, Carrasco E, Casas M, Caballero R, Rodriguez-Lescure A.

Breast Cancer Res. 2014 Apr 12;16(2):R38. doi: 10.1186/bcr3642.


Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)..

Lancet. 2005 May 14-20;365(9472):1687-717.


[Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].

Zhang J, Zhang JH, Liu Y, Hao XM, Fang ZX, Li SL.

Zhonghua Yi Xue Za Zhi. 2007 Dec 11;87(46):3268-71. Chinese.


Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP.

JAMA. 2006 Apr 12;295(14):1658-67. Erratum in: JAMA. 2006 May 24;295(20):2356.


Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups..

Lancet Oncol. 2008 Jan;9(1):23-8.


Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX.

Coates AS, Millar EK, O'Toole SA, Molloy TJ, Viale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M, Gusterson B, Musgrove EA, Sutherland RL.

Breast Cancer Res. 2012 Nov 5;14(6):R143. doi: 10.1186/bcr3348.


HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.

Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr, Sharkey FE, Cruz AB, Kahlenberg MS.

Cancer. 2005 Jun 1;103(11):2252-60.


HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.

Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM.

Clin Cancer Res. 2004 Sep 1;10(17):5670-6.

Items per page

Supplemental Content

Support Center